Advertisement
Advertisement
U.S. markets open in 2 hours 51 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Amgen Inc. (AMGN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
209.24+0.25 (+0.12%)
At close: 4:00PM EDT
209.17 -0.07 (-0.03%)
Pre-Market: 06:22AM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Short-term KST

Short-term KST

Previous Close208.99
Open209.70
Bid0.00 x 800
Ask0.00 x 1000
Day's Range208.53 - 210.50
52 Week Range200.47 - 276.69
Volume1,349,344
Avg. Volume2,551,457
Market Cap118.817B
Beta (5Y Monthly)0.68
PE Ratio (TTM)21.22
EPS (TTM)9.86
Earnings DateNov 02, 2021
Forward Dividend & Yield7.04 (3.36%)
Ex-Dividend DateAug 16, 2021
1y Target Est247.45
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
-8% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for AMGN

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Amgen Inc.
    Analyst Report: Amgen Inc.Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Nexavar and Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), and Lumakras (lung cancer). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
    Rating
    Fair Value
    Economic Moat
    14 days agoMorningstar
View more
  • PR Newswire

    Amgen Announces 2021 Fourth Quarter Dividend

    Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $1.76 per share dividend for the fourth quarter of 2021. The dividend will be paid on December 8, 2021, to all stockholders of record as of the close of business on November 16, 2021.

  • Benzinga

    AstraZeneca Pulls Plug On MCL-1 Cancer Drug Trial

    AstraZeneca Plc (NASDAQ: AZN) has paused an active Phase 1 trial of AZD5991, a direct inhibitor of MCL-1, citing a potential safety issue. Two years ago, the FDA hit Amgen Inc (NASDAQ: AMGN) with a clinical hold on its MCL-1 inhibitor AMG 397 following signs of cardiac toxicity. AstraZeneca's AZD5991 belongs to the same class therapy. The trial suspension, noted on ClinicalTrials.gov, came on October 19: "The study has been put on hold to allow further evaluation of safety-related information,"

  • Benzinga

    Race to Effective Psoriasis Treatment: Can-Fite's Piclidenoson May Edge Over High-Flying Amgen's Otezla. Here's Why

    Photo by Christina Victoria Craft on Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Amgen Inc. (NASDAQ: AMGN) recently announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental New Drug Application (sNDA) for Otezla for the treatment of adults with mild to moderate plaque psoriasis. The company also said the FDA had set a Prescription Drug

Advertisement
Advertisement